@NeoImmuneTech profile picture
NeoImmuneTech @NeoImmuneTech

NIT is a clinical-stage T cell-focused biotech company, dedicated to expand the horizon of Immuno-Oncology and infectious diseases

Joined February 2020
  • Tweets 142
  • Following 66
  • Followers 104
116 Photos and videos
๐Ÿ”” ๋„ค์˜ค์ด๋ฎจํ…, NT-I7๊ณผ oncolytic virus ๋ณ‘์šฉ ์—ฐ๊ตฌ๊ฐ€ ๊ตญ์ œ ํ•™์ˆ ์ง€ Nature communications (IF: 15.7)์— ๊ฒŒ์žฌ. NT-I7์„ ํ™œ์šฉํ•œ โ€˜Expand & Pullโ€™ ์ „๋žต์œผ๋กœ ์ „์‹  T ์„ธํฌ๋ฅผ ์ฆํญ์‹œํ‚ค๊ณ  ์ข…์–‘์œผ๋กœ ์œ ๋„ํ•˜๋Š” ์ƒˆ๋กœ์šด ๋‹จ๊ณ„์  ๋ฉด์—ญ ์น˜๋ฃŒ ์ ‘๊ทผ๋ฒ• ์ œ์‹œ ๐Ÿ“„bit.ly/3MU3FAS #๋„ค์˜ค์ด๋ฎจํ… #NTI7
33
๐Ÿ”” New glioblastoma immunotherapy research featuring NeoImmuneTechโ€™s NT-I7 is now published in Nature Communications(IF: 15.7). A novel โ€œExpand & Pullโ€ strategy for next-generation T cell therapy. ๐Ÿ“„ bit.ly/46eQYXX #NeoImmuneTech #Immunotherapy #NTI7
1
18
๐Ÿ”” ๋„ค์˜ค์ด๋ฎจํ…, FDA ์Šน์ธ ๊ฒธ์ƒ์ ํ˜ˆ๊ตฌ์งˆํ™˜ ์น˜๋ฃŒ์ œEndari ๋ฐ ๊ด€๋ จ ์ œ๋„ค๋ฆญ์˜ ๋ถ๋ฏธ ๋…์  ํŒ๋งค ๋ฐ ๊ฐœ๋ฐœ ๊ถŒ๋ฆฌ ์ตœ์ข… ๊ณ„์•ฝ ์ฒด๊ฒฐ ์™„๋ฃŒ. ์ด๋ฅผ ํ†ตํ•œ ๋ถ๋ฏธ ์‹œ์žฅ์—์„œ์˜ ์ƒ์—…ํ™” ์—ญ๋Ÿ‰ ์ถ•์ ๊ณผ ํ–ฅํ›„ ์ƒ์—…ํ™”๋ฅผ ์œ„ํ•œ ์ค‘์š”ํ•œ ๋ฐœํŒ ๋งˆ๋ จ ๐Ÿ“„ bit.ly/4jg1WBG #๋„ค์˜ค์ด๋ฎจํ… #Endari #ํฌ๊ท€์งˆํ™˜ #NTI7
1
110
๐Ÿ”” NeoImmuneTech finalizes exclusive North American rights to FDA-approved Endariยฎ โ€” securing commercial revenue potential and strengthening the path toward NT-I7 commercialization. ๐Ÿ“„ bit.ly/4pSY0t6 #NeoImmuneTech #Endari #SCD #NTI7
30
๐Ÿ”ฌ ASH 2025 NT-I7 CD19 CAR-T ๋ณ‘์šฉ ์ž„์ƒ, ๊ตฌ๋‘ ๋ฐœํ‘œ โ€“ ์•ˆ์ „์„ฑ ๋ฐ ๋‚ด์•ฝ์„ฑ ์šฐ์ˆ˜, ํ˜„์žฌ 10์ผยท31์ผ ํˆฌ์—ฌ ํ‰๊ฐ€ ์ง„ํ–‰ ์ค‘ NT-I7 CAR-T ๋ฑ์‚ฌ๋ฉ”ํƒ€์†, ์‚ผ์ค‘ ๋ณ‘์šฉ ๋น„์ž„์ƒ, ํฌ์Šคํ„ฐ ๋ฐœํ‘œ โ€“ 100์ผ ์ด์ƒ ์™„์ „ ๊ด€ํ•ด ์œ ์ง€ ๐Ÿ‘‰ bit.ly/48SMCGo #NTI7 #CART #ASH2025
57
๐Ÿ”ฌ ASH 2025: NT-I7 enhanced CAR-T expansion & persistence; preclinical data also showed improved long-term durability with dexamethasone. ๐Ÿ‘‰ bit.ly/3MHgT3B #NTI7 #CART #ASH2025
61
๐Ÿ”ฌ NT-I7 BCMA CAR-T(CARVYKTIยฎ) ๋ณ‘์šฉ ์—ฐ๊ตฌ์ž์ฃผ๋„์ž„์ƒ NIT-128, FDA IND ์Šน์ธ WashU์˜ Michael SladeยทJohn DiPersio ๋ฐ•์‚ฌ ์ฃผ๋„. CAR-T ์น˜๋ฃŒ ํ›„ 14์ผ, 35์ผ 2ํšŒ ํˆฌ์—ฌ๋กœ ๋ฉด์—ญ ํšŒ๋ณต๊ณผ CAR-T ์ง€์†์„ฑ ํ–ฅ์ƒ ํ‰๊ฐ€ ๐Ÿ‘‰ bit.ly/4i6FKcE #NTI7 #CART
1
136
๐Ÿ”ฌFDA clears IND for NIT-128, an IIT led by WashUโ€™s Dr. Michael Slade and Dr. John DiPersio testing NT-I7 CARVYKTIยฎ in multiple myeloma. Two postโ€“CAR-T doses(Day 14 & 35)will assess whether NT-I7 enhances immune recovery and CAR-T persistence.๐Ÿ‘‰bit.ly/4a2jK0w #NTI7 #CART
1
126
๐Ÿš€ ๋„ค์˜ค์ด๋ฎจํ…, NT-I7 BCMA CAR-T ๋ณ‘์šฉ ์ž„์ƒ ็พŽ FDA IND ์ œ์ถœ WashU Medicine์ด ๋‹ค๋ฐœ์„ฑ๊ณจ์ˆ˜์ข…(MM) ํ™˜์ž ๋Œ€์ƒ ์—ฐ๊ตฌ์ž์ฃผ๋„์ž„์ƒ IND๋ฅผ FDA์— ์ œ์ถœ ๋งˆ์ดํด ์Šฌ๋ ˆ์ด๋“œ ์กฐ๊ต์ˆ˜ ์ฃผ๋„, ์กด ๋””ํผ์‹œ์˜ค ๊ต์ˆ˜ ํ˜‘๋ ฅ NT-I7์˜ CAR-T ๋ณ‘์šฉ ์ „๋žต BCMA๋กœ ํ™•์žฅ ๐Ÿ“„ bit.ly/4388ED4 #NeoImmuneTech #NTI7 #CART
28
๐Ÿš€ NeoImmuneTech Announces IND for NT-I7 BCMA CAR-T Trial WashU Med filed IND for Ph1 of NT-I7 BCMA CAR-T in multiple myeloma, led by Dr. Slade in collab with Dr. DiPersio, expanding NT-I7's CAR-T strategy ๐Ÿ“ท bit.ly/3Jw6kyY #NeoImmuneTech #NTI7 #CART
22
๐Ÿ”ฌ ็พŽ FDA, CAR-T ๋ณ‘์šฉ NT-I7 ๋ฐ˜๋ณตํˆฌ์—ฌ ์—ฐ๊ตฌ์ž ์ฃผ๋„ ์ž„์ƒ ์Šน์ธ John DiPersioยทZachary D. Crees ๋ฐ•์‚ฌ ์ฃผ๋„, 10์ผ์ฐจยท31์ผ์ฐจ ํˆฌ์—ฌ ์ „๋žต์œผ๋กœ CAR-T ์ง€์†์„ฑยทํšจ๊ณผ ํ–ฅ์ƒ ๋ชฉํ‘œ ๐Ÿ‘‰ bit.ly/4fy1DAf #NTI7 #CART #์ž„์ƒ์‹œํ—˜ #๋ฉด์—ญํ•ญ์•”์ œ
35
๐Ÿ”ฌ FDA has cleared an IIT led by Drs. John DiPersio & Zachary D. Crees testing repeat dosing of NT-I7 (efineptakin alfa) post CAR-T in r/r LBCL. Two-dose strategy on Days 10 & 31 aims to boost CAR-T persistence & durability. ๐Ÿ‘‰ bit.ly/46Slwjq#NTI7 #CART #Immunotherapy
29
NT-I7ยทCAR-T ๋ณ‘์šฉ ํ›„์† ์ž„์ƒ, ็พŽ FDA์— IND ์ œ์ถœ! ์›Œ์‹ฑํ„ด๋Œ€ John DiPersio ๋ฐ•์‚ฌ ์ฃผ๋„ ์—ฐ๊ตฌ์ž ์ž„์ƒ์—์„œ#LBCL ํ™˜์ž ๋Œ€์ƒ์œผ๋กœ NT-I7 10์ผยท31์ผ ๋ฐ˜๋ณต ํˆฌ์—ฌ ์ „๋žต์„ ํ†ตํ•ด ์น˜๋ฃŒ ๋ฐ˜์‘์„ ๊ทน๋Œ€ํ™” ํ•˜๊ณ ์ž ํ•ฉ๋‹ˆ๋‹ค. ๐Ÿ“„ bit.ly/46Hfe5Y #NeoImmuneTech #Immunotherapy #CART
30
IND submitted to the FDA for a follow-up trial of #NTI7 CAR-T! Led by Dr. John DiPersio, this IIT explores a repeated dosing strategy (Day 10 & 31) in #LBCL patients. ๐Ÿ“„bit.ly/3IpyJGa #NeoImmuneTech #Immunotherapy #CART
25
๋„ค์˜ค์ด๋ฎจํ…, NT-I7 CAR-T ๋ณ‘์šฉ ์ž„์ƒ ์ตœ์ข… ๊ฒฐ๊ณผ ๋ฐœํ‘œ ๐Ÿ’ฅ๊ณ ์šฉ๋Ÿ‰๊ตฐ ๋ฐ˜์‘๋ฅ  100% ๋ฐ 6๊ฐœ์›” ์ด์ƒ ์ง€์† 88% ๐Ÿ›ก๏ธ NT-I7 ํˆฌ์—ฌ ์ดํ›„ CRSยทICANS ์ด์ƒ๋ฐ˜์‘ โ€˜0๊ฑดโ€™ ๐ŸงฌRP2D 720 ฮผg/kg BIO 2025์—์„œ ๊ธ€๋กœ๋ฒŒ ์ œ์•ฝ์‚ฌ์™€ ํ›„์† ๋…ผ์˜๋ฅผ ์ด์–ด ๋‚˜๊ฐˆ ์˜ˆ์ •์ž…๋‹ˆ๋‹ค ๐Ÿ”— bit.ly/43BMnxZ #๋„ค์˜ค์ด๋ฎจํ… #CAR_T #NTI7 #๋ฉด์—ญํ•ญ์•”
84
Final results from NeoImmuneTechโ€™s Ph1b trial of NT-I7 CAR-T! 100% ORR in high-dose cohort and 88% maintained response >6mo๐Ÿ›ก๏ธ No CRS or ICANS after NT-I7 ๐Ÿงฌ RP2D: 720 ฮผg/kg ๐Ÿค Partner talks ongoing โ€” meet us at #BIO2025! ๐Ÿ”—bit.ly/4mnfYCA #CAR_T #NTI7 #Immunotherapy
2
53
๋„ค์˜ค์ด๋ฎจํ…์ด #AACR2025 ์—์„œ ๋‘๊ฒฝ๋ถ€์•” ๋น„์ž„์ƒ ๋ชจ๋ธ์—์„œ ๋ฆผํ”„๊ตฌ ํšŒ๋ณต๊ณผ ํ•ญ์•” ์‹œ๋„ˆ์ง€๋ฅผ ์ž…์ฆํ•œ ๊ฒฐ๊ณผ๋ฅผ ๋ฐœํ‘œํ–ˆ์Šต๋‹ˆ๋‹ค. ๐Ÿงช ์‹œ์Šคํ”Œ๋ผํ‹ด, ๋ฉด์—ญ๊ด€๋ฌธ์–ต์ œ์ œ ๋ณ‘์šฉ ์‹œ ๊ฐ•๋ ฅํ•œ ํšจ๊ณผ ๐Ÿ’ก ๋ฉด์—ญ์„ธํฌ ๋ถ„์„ ํ†ตํ•ด Tpex ์„ธํฌ ํ™•์žฅ ํ™•์ธ #๋ฉด์—ญํ•ญ์•”์ œ #CancerResearch #Immunotherapy ๐Ÿ”—bit.ly/3GGTM6e
194
๐Ÿ“ข #NeoImmuneTech @#AACR2025! NT-I7 restores lymphopenia & boosts anti-cancer efficacy in HNSCC models ๐Ÿ”ฌ ๐Ÿ’ฅStrong synergy with Cisplatin anti-PD-1 ๐Ÿ’กNT-I7 expands CD8 Tpex cells, suggesting combo therapy potential #CancerResearch #Immunotherapy ๐Ÿ”—bit.ly/3GXQrj6
80
We are attending #BioPartnering at JPM Week (January 13โ€“16, 2025) in San Francisco. Our focus is NTโ€‘I7, a longโ€‘acting ILโ€‘7 that may amplify Tโ€‘cell in immunotherapy. For more details or to schedule a meeting, please email Dr. Dan Rho at drho@neoimmunetech.com.
98
3 key milestones for NT-I7 in Q4 2024! ๐Ÿงช Primate study underway for #acuteradiationsyndrome (ARS) ๐Ÿฉบ #ASH2024 NT-I7 aids T cell recovery after radiation ๐Ÿงฌ Frontiers in Immunology: NT-I7 boosts immuno-oncology outcomes in #lymphopenia. Read more ๐Ÿ”— bit.ly/40jZa6F
1
79
Load more